IP Library Granted Patent US 10,160,953
Granted Patent B2
US 10,160,953 · App. 14/886,577 · Granted Dec 25, 2018

Method for culturing skeletal muscle for tissue engineering

Inventors: James J. Hickman (Orlando, FL); Mainak Das (Orlando, FL); John W. Rumsey (Orlando, FL)
Assignee: University of Central Florida Research Foundation, Inc.
C12N5/0652C12N5/0619C12N5/0658C12N2500/05C12N2500/46C12N2500/90C12N2500/99C12N2501/40C12N2502/1335C12N2533/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,160,953
App. No.
14/886,577
Granted
Dec 25, 2018
Kind
B2
Abstract

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal.

Claims (16)

1. A method of maintaining a muscle cell culture, the method comprising:

maintaining the muscle cell culture in a serum-free maintenance medium comprising the components at the concentrations listed in Table 3, the components at the concentrations listed in Table 4, the components at the concentrations listed in Table 5, creatine, estrogen, and cholesterol wherein the cells in the muscle cell culture consist of muscle cells.

2. The method of claim 1 , wherein the muscle cell culture is maintained in the serum-free maintenance medium for at least 30 days.

3. The method of claim 2 , wherein the muscle cell culture is maintained in the serum-free maintenance medium for at least 50 days.

4. The method of claim 1 , further comprising plating the muscle cell culture onto a non-biological growth substrate prior to maintaining the muscle cell culture in the serum-free maintenance medium.

5. The method of claim 4 , wherein the non-biological growth substrate comprises a silane molecule.

6. The method of claim 5 , wherein the non-biological growth substrate is trimethoxy-silylpropyl-diethylenetriamine (DETA).

7. The method of claim 1 , further comprising plating the muscle cell culture at a density of 700 to 1000 muscle cells per square millimeter prior to maintaining the muscle cell culture in the serum-free maintenance medium.

8. The method of claim 1 , further comprising replenishing the serum-free maintenance medium every 1 to 5 days.

9. The method of claim 8 , further comprising replenishing the serum-free maintenance medium every 3 days.

10. The method of claim 1 , further comprising incubating the muscle cell culture in a first serum-free medium prior to maintaining the muscle cell culture in the serum-free maintenance medium.

11. The method of claim 10 , wherein the first serum-free medium comprises a factor selected from the group consisting of vascular endothelial growth factor (VEGF), acidic fibroblast growth factor (FGF), heparin sulfate, leukemia inhibitory factor (LIF), vitronectin, ciliary neurotrophic factor (CNTF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), cardiotrophin-1 (CT-1), cholesterol, tumor necrosis factor alpha (TNF-alpha), platelet derived growth factor (PDGF), vasoactive intestinal peptide, insulin-like growth factor 1, neutrophil activating protein (NAP), r-Apolipoprotein, laminin, beta amyloid, tenascin-C protein, rr-sonic hedgehog, and rr-agrin.

12. The method of claim 11 , wherein the first serum-free medium comprises vitronectin.

13. The method of claim 12 , wherein the first serum-free medium is a mixture of approximately equal volumes of the medium composition of Table 1 and the medium composition of Table 2.

14. The method of claim 10 , wherein the muscle cell culture is maintained in the first serum-free medium from 2 to 6 days.

15. The method of claim 14 , wherein the muscle cell culture is maintained in the first serum-free medium for 4 days.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2018
From: HICKMAN, JAMES J.; DAS, MAINAK; RUMSEY, JOHN W.
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 046613/0148 →
CONFIRMATORY LICENSE Recorded Aug 16, 2017
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043569/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2016
From: HICKMAN, JAMES J.
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 038334/0909 →
Continuity (3)
Continuation 12765399 · Apr 22, 2010
Provisional Application 61171968 · Apr 23, 2009
Related Publication 20160068812A1 · Mar 10, 2016